iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

Significant Transactions (Narrative) (Details)					3 Months Ended		6 Months Ended		12 Months Ended
Significant Transactions (Narrative) (Details)	Sep. 19, 2022 USD ($) shares	Sep. 16, 2022 USD ($)	Nov. 01, 2021 USD ($) lease $ / shares shares	Aug. 23, 2021 USD ($) shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) item	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)
General and administrative expenses					$ 2,961,000	$ 7,794,000	$ 6,508,000	$ 12,882,000
Value of common stock issued					30,000		$ 30,000			$ 20,000
Accrued expenses - noncurrent										527,000
Purchase price allocated				$ 7,500,000
Secured Term Loan
Secured term loan			$ 22,375,000							13,057,000
Interest rate (as percent)			3.25%
Cost incurred to attain debt										$ 120,000
RubrYc Therapeutics Inc [Member]
Estimated fair value		$ 650,000
Milestone payments	$ 5,000,000
Amount advanced		484,000
Transaction costs		208,000
Finance leases		$ 814,000	$ 814,000
Impairment of current prepaid expense									$ 288,000
Impairment of noncurrent prepaid expense									864,000
Number of shares issued \| shares	5,117
Value of common stock issued	$ 1,000,000
Number of equipment leases \| lease			3
Purchase price allocated	$ 1,342,000
College Station Investors LLC And Bryan Capital [Member]
Total purchase price			$ 28,750,000
Cash payment			28,000,000
Fair market value of property			$ 151,450
Percentage of base rent			6.50%
Cash consideration for equity interest acquired			$ 50,000
Number of warrants issued \| shares			2,579
Warrants, exercise price per share \| $ / shares			$ 665
Shares issued under the Warrant \| shares			579
Fair value of the warrant			$ 217,255
College Station Investors LLC And Bryan Capital [Member] \| Secured Term Loan
Secured term loan			$ 22,375,000
College Station Investors LLC And Bryan Capital [Member] \| IBio CMO Preferred Tracking Stock
Warrants issuable \| shares			1
Percentage of equity interest			0.01%
Separation Agreement and General Release [Member]
General and administrative expenses						$ 2,130,000
Period of bi-monthly installments of current base salary							24 months
Period of bi-monthly installments of target bonus							24 months
Maximum period for coverage of health insurance							18 months
COBRA subsidy period							18 months
Number of times on which lump sum cash payment tis o be made \| item							6
Accrued expenses					$ 1,100,000		$ 1,100,000
Collaboration, Option and License Agreement [Member] \| Immune-Oncology Antibodies (RTX-003) [Member] \| RubrYc Therapeutics Inc [Member]
Collaboration and license agreement, agreement term				5 years
Collaboration, Option and License Agreement [Member] \| Immune-Oncology Antibodies (RTX-003) [Member] \| No Biosimilar Product has been Approved [Member] \| RubrYc Therapeutics Inc [Member]
Collaboration and license agreement, royalty payment term				10 years
Series A-2 Preferred Stock [Member]
Purchase price allocated									$ 1,760,000
Series A-2 Preferred Stock [Member] \| Series A-2 Preferred Stock [Member]
Purchase price allocated				$ 1,760,000
Series A-2 Preferred Stock [Member] \| Stock Purchase Agreement [Member] \| Immune-Oncology Antibodies (RTX-003) [Member] \| RubrYc Therapeutics Inc [Member]
Stock purchase agreement, number of shares purchased \| shares				2,864,345
Stock purchase agreement, value of shares purchased				$ 7,500,000